SIGA Technologies logo

SIGA TechnologiesNASDAQ: SIGA

Profile

Sector:

Healthcare

Country:

United States

IPO:

10 September 1997

Next earnings report:

12 March 2025

Last dividends:

25 March 2024

Next dividends:

N/A
$435.57 M
-77%vs. 3y high
64%vs. sector
-89%vs. 3y high
8%vs. sector
-81%vs. 3y high
64%vs. sector
-80%vs. 3y high
44%vs. sector

Price

after hours | 108 min ago
$6.10$0.00(0.00%)
$10.01 M$1.34 M

Analysts recommendations

Institutional Ownership

SIGA Latest News

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
globenewswire.com08 November 2024 Sentiment: NEGATIVE

SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.

SIGA Technologies, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SIGA
accesswire.com07 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Technologies, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SIGA
accesswire.com05 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Technologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - SIGA
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

Shareholders That Lost Money on SIGA Technologies, Inc. (SIGA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - SIGA
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
globenewswire.com31 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
globenewswire.com23 October 2024 Sentiment: NEGATIVE

SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.

SIGA Technologies, Inc. (SIGA) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
accesswire.com23 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
globenewswire.com22 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement with Vanderbilt University to obtain a license to a portfolio of preclinical fully human monoclonal antibodies (mAbs) which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox. Under the agreement, SIGA has exercised its option to license the exclusive rights to develop, manufacture, and commercialize these mAbs globally.

SIGA Technologies, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SIGA
accesswire.com15 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024, video was released of Dr. Varma detailing how he and SIGA were engaged in a media "spin" campaign to salvage TPOXX as a mpox treatment and preserve the Company's stock price despite disappointing top line results in the PALM 007 clinical trial.

What type of business is SIGA Technologies?

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

What sector is SIGA Technologies in?

SIGA Technologies is in the Healthcare sector

What industry is SIGA Technologies in?

SIGA Technologies is in the Drug Manufacturers - Specialty & Generic industry

What country is SIGA Technologies from?

SIGA Technologies is headquartered in United States

When did SIGA Technologies go public?

SIGA Technologies initial public offering (IPO) was on 10 September 1997

What is SIGA Technologies website?

https://www.siga.com

Is SIGA Technologies in the S&P 500?

No, SIGA Technologies is not included in the S&P 500 index

Is SIGA Technologies in the NASDAQ 100?

No, SIGA Technologies is not included in the NASDAQ 100 index

Is SIGA Technologies in the Dow Jones?

No, SIGA Technologies is not included in the Dow Jones index

When was SIGA Technologies the previous earnings report?

No data

When does SIGA Technologies earnings report?

The next expected earnings date for SIGA Technologies is 12 March 2025